Hikal Ltd Q1 FY26 – Sales ₹380 Cr (-6.5%), PAT Loss ₹-22 Cr (from +₹18 Cr). P/E 52: When FDA Calls, Profits Crawl.
1. At a Glance
Quarterly headline: Revenue ₹380 Cr (down 6.5% YoY), loss of ₹22 Cr after FDA slapped their Jigani pharma plant with an OAI (Official Action Indicated) tag. Market cap still ~₹3,300 Cr, because desi investors never met a loss-making pharma company they didn’t love. OPM shrank to 7% from 17% last year, debt stands at ₹765 Cr. Basically, Hikal is trying to be Syngene + PI Industries + Divi’s, but currently looks like “Hikal Bina Profit Wala.”
2. Introduction
Imagine a pharma + agrochem cocktail: one shot of APIs, one shot of crop protection, a sprinkle of CDMO, and a garnish of R&D buzzwords. That’s Hikal. Founded as a partner-to-all, today they run 5 plants, 24 production blocks, 3,000 staff, 250 scientists, 26 PhDs. On paper, this is “Make in India” on steroids.
But reality check: profits are slipping, debt is mounting, and FDA inspectors just turned Jigani unit into “Jigna nahin, jiggle mat.” A pharma plant with OAI is like a restaurant with FSSAI shutdown notice: fancy menu, but customers walk away.
The company’s stock is down 30% in a year. Yet, valuations cling to 52× trailing P/E. Auditors like me look at this and mutter, “Bhai, yeh balance sheet ka SWOT hai ya roast platter?”
Reader poll: would you eat food from a hotel with repeated health violations, if they promised “new menu soon”?
CDMO: 13–14 molecules in pipeline, 2 launches by FY26. They want innovator clients but FDA keeps innovating penalties.
Crop Protection (38%): Agrochemical actives & intermediates. They also manufacture battery chemicals and personal care intermediates — because diversification = survival.
Animal Health: New facility at Panoli for pet & livestock APIs. Basically, if your dog sneezes, one day Hikal pill may be behind it.
Sounds good, but margins don’t lie. Crop protection has turned volatile, pharma is FDA-dependent, CDMO is promise-land, and animal health is just starting.
4. Financials Overview
Source table
Metric
Latest Qtr (Q1 FY26)
YoY Qtr (Q1 FY25)
Prev Qtr (Q4 FY25)
YoY %
QoQ %
Revenue
380
407
552
-6.5%
-31.2%
EBITDA
25
58
123
-56.9%
-79.7%
PAT
-22
5
50
-539%
-144%
EPS (₹)
-1.82
0.41
4.07
N/A
N/A
Commentary: The auditor in me says: “Sales slipping, margins squeezed, losses ballooning. If this were a school report card, parents would send Hikal to tuitions.” Annualised EPS is negative, so P/E not meaningful. CMP is living on hope.
